Author Login

Correspondence to Author: Aqsa Ghaffar¹ , Yunna Xie, PhD² , Peter Antinozzi, PhD⁵ , Haoming Qiu, MD⁴ , Julie Ryan Wolf, PhD, MPH^3,4. 

¹ School of Medicine & Dentistry.
² Public Health Sciences.
³ Dermatology.
⁴ Radiation Oncology, University of Rochester Medical Center, Rochester, NY, USA.
⁵ Bravida Medical, Geneva, IL, USA.

DOI: 10.52338/Tjoro.2025.4355

Abstract:

Introduction:Radiation dermatitis (RD) occurs in up to 95% of patients receiving radiation therapy (RT) for cancer treatment, affecting 800,000 patients annually. We evaluated the safety and feasibility of Silverlon dressing for RD management in breast cancer patients undergoing RT.

Methods:This single arm, single institution, open-label clinical trial assessed the safety and feasibility of Silverlon dressing for managing RD in breast cancer patients undergoing RT (n=30). RD severity (e.g., RTOG grade; Radiation Induced Skin Reaction Assessment Scale (RISRAS)) was captured mid-RT, end-RT, and 2-weeks post-RT. Dermatology Life Quality Index was administered at baseline, mid-RT, end of RT, and 2-weeks post-RT. Potential efficacy was explored using a historical 3:1 matched control cohort of 90 patients who received standard RD care during RT as a comparator group. All statistical analyses were conducted at a significance level of 0.05.

Results:Minimal withdrawals and adverse events, high patient compliance, and patient recommendation of Silverlon dressing underscore its safety for RD management. Silverlontreated subjects did not experience increased RD severity compared to historical matched controls using standard of care (1.27 [1.07, 1.46] vs. 1.39 [1.25, 1.52], p=0.351). Additional comparison to a published cohort of 169 breast cancer patients suggests that Silverlon may be better than standard care management for RD (1.27 [1.07, 1.46] vs. 1.57 [1.42, 1.68], p=0.027).

Conclusions:This study established the safety, feasibility, and potential benefit of Silverlon dressing for RD management. Further, Silverlon may have reduced the need for multiple topical treatments for skin reactions during RT. Larger and more diverse clinical trials should examine the extent of Silverlon’s therapeutic benefit for skin during RT.

Citation:

Dr. Julie Ryan Wolf, PhD, Safety And Feasibility Of Silverlon Dressing For The Management Of Radiation Dermatitis. The Journal of Radiation Oncology 2025.